RE:RE:Amber Kanwar's 'deep' dive into CXR pricingDoesn't seem to matter at this point, everytime the stock is mentioned in the news it seems to tank. The article makes some good points on volume vs price, but it leaves you feeling that the waters are a little muddy and investors don't seem to have the appetite to dive in at this point for fear of breaking their neck. I'd like to see more support at $33 because the next stop is $30 and if it breaks its anyones guess how low it goes. Even an earnings beat isn't going to push it higher percentage wise if the stock hits $25. We need some big buyers fast cause they trend isn't looking good right now.
Marcel7 wrote: Well there is this:
"In fact, since Concordia took ownership in October, the price of the pink eye drug, Fucithalmic, is
actually unchanged. The price increased 50 per cent right before Concordia took ownership."
Marcel
cashflow98 wrote:
https://www.bnn.ca/News/2016/5/6/Concordia-Healthcare-Diving-deep-into-claims-of-sky-high-prices.aspx